Live Breaking News & Updates on Observed After

Stay updated with breaking news from Observed after. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

/PRNewswire/ Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies. ....

Ligand Pharmaceuticals Incorporated , Drug Administration , Therapeutics Inc , Placebo Adjusted Mean Weight Loss , Observed After , Day Study , Flow Rates , Related Adverse , Obesity Planned , Call Scheduled , Viking Therapeutics , Brian Lian , Body Weight Following , Daily Dosing , Related Adverse Events Following , Ligand Pharmaceuticals ,

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo
Up to 13.1% Placebo-Adjusted Mean Weight. ....

Drug Administration , Ligand Pharmaceuticals Incorporated , Therapeutics Inc , Study Achieves Primary , Secondary Endpoints , Body Weight , Placebo Adjusted Mean Weight Loss , From Baseline , Observed After , Week Study , Treatment Emergent Adverse Events Considered Mild , Call Scheduled , Viking Therapeutics , Body Weight Following , Once Weekly Dosing , Common Gastrointestinal , Ligand Pharmaceuticals ,

Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia

LDL-C Reductions Up to 55% and Blood PCSK9 Protein Reductions Up to 84% Observed After a Single Infusion of VERVE-101 at Potentially Therapeutic Doses Safety Profile Supports Continued Development of. ....

United Kingdom , United States , New York , New Zealand , Sekar Kathiresan , Andrew Bellinger , Jen Robinson , Ashlea Kosikowski , Deepakl Bhatt , Safety Profile Supports Continued Development , Company To Host Conference Call , Exchange Commission , Verve Therapeutics Inc , Drug Administration , Icahn School Of Medicine , Observed After , Single Infusion , Potentially Therapeutic , Profile Supports Continued Development , Initiate Expansion Cohort , Host Conference Call , Webcast Today , Mount Sinai Fuster Heart Hospital , Valentin Fuster Professor , Cardiovascular Medicine , Icahn School ,

Verve Therapeutics Announces Interim Data for VERVE-101

LDL-C Reductions Up to 55% and Blood PCSK9 Protein Reductions Up to 84% Observed After a Single Infusion of VERVE-101 at Potentially Therapeutic Doses . ....

United Kingdom , United States , New Zealand , New York , Deepakl Bhatt , Sekar Kathiresan , Ashlea Kosikowski , Andrew Bellinger , Jen Robinson , Verve Therapeutics Inc , Exchange Commission , Drug Administration , Company To Host Conference Call , Safety Profile Supports Continued Development , Icahn School Of Medicine , Observed After , Single Infusion , Potentially Therapeutic , Profile Supports Continued Development , Initiate Expansion Cohort , Host Conference Call , Webcast Today , Mount Sinai Fuster Heart Hospital , Valentin Fuster Professor , Cardiovascular Medicine , Icahn School ,

Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia

LDL-C Reductions Up to 55% and Blood PCSK9 Protein Reductions Up to 84% Observed After a Single Infusion of VERVE-101 at Potentially Therapeutic Doses Safety Profile Supports Continued Development of. ....

United Kingdom , United States , New Zealand , New York , Jen Robinson , Andrew Bellinger , Deepakl Bhatt , Sekar Kathiresan , Ashlea Kosikowski , Globenewswire Inc , Icahn School Of Medicine , Verve Therapeutics Inc , Safety Profile Supports Continued Development , Company To Host Conference Call , Drug Administration , Exchange Commission , Observed After , Single Infusion , Potentially Therapeutic , Profile Supports Continued Development , Initiate Expansion Cohort , Host Conference Call , Webcast Today , Sinai Fuster Heart Hospital , Fuster Professor , Cardiovascular Medicine ,